ScreenerHero

SABS SAB Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · sab.bio
2.880USD-1.71%Mkt Cap: 262.04M $P/E: —

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap262.04M USD
Enterprise Value169.09M USD
Revenue (TTM)—
Gross Profit-48.27M USD
Net Income (TTM)13.27M USD
Revenue/Share—
Last Price2.880 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees86
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.07
PEG—
EV/EBITDA-2.46
EV/Revenue—
P/S—
P/B1.14
EPS (TTM)-1.29
EPS (Forward)-0.95
52W Range
1.85031% of range5.150
52W High5.150 USD
52W Low1.850 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE8.76%
ROA7.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-44.78M USD
CapEx (TTM)933.16K USD
FCF Margin—
FCF Yield-11.01%
Net Debt-97.50M USD
Net Debt/EBITDA1.42
Balance Sheet
Debt/Equity0.04
Current Ratio9.22
Quick Ratio8.93
Book Value/Sh2.57 USD
Cash/Share1.13 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 5, 2024
Analyst Consensus
Rating—
Target (Mean)11.64 USD
Upside (mean)+304.0%
Target Range6.000 USD – 16.00 USD
6.000+304.0% to mean16.00
# Analysts11
Ownership
Shares Out.90.99M
Float62.04M
Insiders0.71%
Institutions75.39%
Short Interest
Short Ratio11.9d
Short % Float4.09%
Short % Out.3.96%
Shares Short3.60M
Short (prev mo.)4.63M
Technical
SMA 503.575 (-19.5%)
SMA 2003.771 (-23.6%)
Beta0.58
S&P 52W Chg16.45%
Avg Vol (30d)560.20K
Avg Vol (10d)809.04K
Technical Indicators
RSI (14)26.9
MACD-0.1820
MACD Signal-0.1408
MACD Hist.-0.0412
BB Upper3.770 USD
BB Middle3.306 USD
BB Lower2.843 USD
BB Width28.03%
ATR (14)0.1787 USD
Vol Ratio (20d)1.04x